Immune reconstitution inflammatory syndrome (IRIS) is an immuno-pathologic reaction to quiescent opportunistic microbial pathogens upon restoration of underlying immune defects. Here we report a Honduran patient with HIV/AIDS who developed a facial rash worsening on antiretroviral therapy and increasing CD4 count. Culture and PCR analysis from the skin biopsy identified Leishmania panamensis, which was effectively treated with long-term liposomal amphotericin B. This is the first report of mucocutaneous leishmaniasis (MCL)-associated IRIS due to L. panamensis.
Get full access to this article
View all access options for this article.
References
1.
MullerM, WandelS, ColebundersR, et al.: Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and meta-analysis. Lancet Infect Dis, 2010; 10(4):251–261.
2.
ShelburneSA3rd, HamillRJ, Rodriguez-BarradasMC, et al.: Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore), 2002; 81(3):213–227.
3.
MahnkeYD, GreenwaldJH, DerSimonianR, et al.: Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood, 2012; 119(13):3105–3112.
4.
LawnSD and WilkinsonRJ: Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol, 2006; 28(11):625–633.
5.
McGwireBS and SatoskarAR: Leishmaniasis: Clinical syndromes and treatment. QJM, 2014; 107(1):7–14.
6.
MurrayHW: Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS, 1999; 13(8):459–465.
7.
BadaroR, GoncalvesLO, GoisLL, et al.: Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: A literature review. J Int Assoc Provid AIDS Care, 2014. [Epub ahead of print]; DOI: 10.1177/2325957414555225.
8.
GoisL, BadaroR, SchooleyR, and GrassiM: Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): A case report. BMC Infect Dis, 2015; 15(1):38.
9.
Posada-VergaraMP, LindosoJA, TolezanoJE, et al.: Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis, 2005; 192(10):1819–1822.
10.
VelezI, AgudeloS, RobledoS, et al.: Diffuse cutaneous leishmaniasis with mucosal involvement in Colombia, caused by an enzymatic variant of Leishmania panamensis. Trans R Soc Trop Med Hyg, 1994; 88(2):199.
11.
Machado-CoelhoGL, CaiaffaWT, GenaroO, et al.: Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg, 2005; 99(1):55–61.
12.
Pereira LdeO, Maretti-MiraAC, RodriguesKM, et al.: Severity of tegumentary leishmaniasis is not exclusively associated with Leishmania RNA virus 1 infection in Brazil. Mem Inst Oswaldo Cruz, 2013; 108(5):665–667.
13.
ScottP: Leishmania—a parasitized parasite. N Engl J Med, 2011; 364(18):1773–1774.
14.
IvesA, RonetC, PrevelF, et al.: Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science, 2011; 331(6018):775–778.
15.
AmersonEH and MaurerTA: Immune reconstitution inflammatory syndrome and tropical dermatoses. Dermatol Clin, 2011; 29(1):39–43.
16.
CerfBJ, JonesTC, BadaroR, et al.: Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis, 1987; 156(6):1030–1033.
17.
TrujilloCM, RobledoSM, FrancoJL, et al.: Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis-Th1 immune response in comparison to patients with localized cutaneous leishmaniasis. Parasite Immunol, 2002; 24(9–10):455–462.
18.
NylenS and, EidsmoL: Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunol, 2012; 34(12):551–561.
19.
SanguezaOP, SanguezaJM, StillerMJ, and SanguezaP: Mucocutaneous leishmaniasis: A clinicopathologic classification. J Am Acad Dermatol, 1993; 28(6):927–932.
